Psychological Intervention for Improving Cognitive Function in Cancer Survivors: A Literature Review and Randomized Controlled Trial

Frontiers in Oncology

Volumn 5, Issue , 2015, Pages

  King, Summer ^a   Green, Heather Joy ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

cancer; cognitive function; cognitive rehabilitation; group; randomized controlled trial; survivorship

Indexed keywords

EID: 84978323229     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00072     Document Type: Article

References (116)

1. Janelsins MC Kohli S Mohile SG Usuki K Ahles TA Morrow GR. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol (2011) 38(3):431–8.10.1053/j.seminoncol.2011.03.01421600374
2. Poppelreuter M Weis J Kulz AK Tucha O Lange KW Bartsch HH. Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer (2004) 40(1):43–9.10.1016/j.ejca.2003.08.00114687788
3. Wefel JS Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep (2012) 12(3):267–75.10.1007/s11910-012-0264-922453825
4. Ahles TA Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer (2007) 7(3):192–201.10.1038/nrc207317318212
5. Dietrich J Monje M Wefel J Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist (2008) 13(12):1285–95.10.1634/theoncologist.2008-013019019972
6. Curt GA. Fatigue in cancer: like pain, this is a symptom that physicians can and should manage. BMJ (2001) 322(7302):1560.10.1136/bmj.322.7302.1560
7. Boykoff N Moieni M Subramanian S. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv (2009) 3(4):223–32.10.1007/s11764-009-0098-x19760150
8. Hutchinson AD Hosking JR Kichenadasse G Mattiske JK Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev (2012) 38(7):926–34.10.1016/j.ctrv.2012.05.00222658913
9. Pullens MJJ De Vries J Roukema JA. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology (2010) 19(11):1127–38.10.1002/pon.167320020424
10. Wefel JS Kayl AE Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer (2004) 90(9):1691–6.10.1038/sj.bjc.660177215150608
11. Hodgson KD Hutchinson AD Wilson CJ Nettelbeck T. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev (2013) 39(3):297–304.10.1016/j.ctrv.2012.11.00123219452
12. Jim HSL Phillips KM Chait S Faul LA Popa MA Lee Y-H et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol (2012) 30(29):3578–87.10.1200/JCO.2011.39.564022927526
13. Schagen SB van Dam FS Muller MJ Boogerd W Lindeboom J Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer (1999) 85(3):640–50.10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G10091737
14. McDougall GJ Jr Oliver JS Scogin F. Memory and cancer: a review of the literature. Arch Psychiatr Nurs (2014) 28(3):180–6.10.1016/j.apnu.2013.12.005
15. Ahles TA Saykin AJ Furstenberg CT Cole B Mott LA Skalla K et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol (2002) 20(2):485–93.10.1200/JCO.20.2.48511786578
16. Cruzado J López-Santiago S Martínez-Marín V José-Moreno G Custodio A Feliu J. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer (2014) 22(7):1815–23.10.1007/s00520-014-2147-x24535240
17. Cull A Hay C Love SB Mackie M Smets E Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer (1996) 74:1674–9.10.1038/bjc.1996.6088932354
18. van Dam FSAM Schagen SB Muller MJ Boogerd W Wall E Fortuyn MED et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard- dose chemotherapy. J Natl Cancer Inst (1998) 90(3):210–8.10.1093/jnci/90.3.2109462678
19. Wefel JS Lenzi R Theriault RL Davis RN Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer (2004) 100(11):2292–9.10.1002/cncr.20272
20. Ahn S Park B Noh D Nam S Lee E Lee M et al. Health-related quality of life in disease-free survivors of breast cancer with the general population. Ann Oncol (2007) 18(1):173–82.10.1093/annonc/mdl33317030550
21. Jenkins V Shilling V Fallowfield L Howell A Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology (2004) 13(1):61–6.10.1002/pon.70914745746
22. Bender CM Paraska KK Sereika SM Ryan CM Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage (2001) 21(5):407–24.10.1016/S0885-3924(01)00268-811369162
23. Green HJ Pakenham KI Gardiner RA. Cognitive deficits associated with cancer: a model of subjective and objective outcomes. Psychol Health Med (2005) 10(2):145–60.10.1080/13548500500093308
24. Hess LM Insel KC. Chemotherapy-related change in cognitive function: a conceptual model. Oncol Nurs Forum (2007) 34(5):981–94.10.1188/07.ONF.981-99417878127
25. Tannock IF Ahles TA Ganz PA Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol (2004) 22(11):2233–9.10.1200/JCO.2004.08.09415169812
26. Vearncombe KJ Pachana NA. Impact of health, treatment and psychological factors on cognitive functioning after chemotherapy for early breast cancer. Aust Psychol (2009) 44(4):235–47.10.1080/00050060903096652
27. Bowling A. Measuring Health: A Review of Quality of Life Measurement Scales. Buckingham: Open University Press (1991).
28. Montazeri A Vahdaninia M Harirchi I Ebrahimi M Khaleghi F Jarvandi S. Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. BMC Cancer (2008) 8(1):330.10.1186/1471-2407-8-33019014435
29. Quinten C Coens C Mauer M Comte S Sprangers MAG Cleeland C et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from eortc clinical trials. Lancet Oncol (2009) 10(9):865–71.10.1016/S1470-2045(09)70200-119695956
30. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes (2009) 7(1):102.10.1186/1477-7525-7-10220030832
31. Lemieux J Goodwin PJ Bordeleau LJ Lauzier S Théberge V. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst (2011) 103(3):178–231.10.1093/jnci/djq50821217081
32. Mols F Vingerhoets AJJM Coebergh JW van de Poll-Franse LV. Quality of life among long-term breast cancer survivors: a systematic review. Eur J Cancer (2005) 41(17):2613–9.10.1016/j.ejca.2005.05.01716226458
33. Mehnert A Scherwath A Schirmer L Schleimer B Petersen C Schulz-Kindermann F et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns (2007) 66(1):108–18.10.1016/j.pec.2006.11.00517320337
34. Green HJ. The context of adjustment: qualitative reports from Australian men being treated for non-localised prostate cancer. Clin Psychol (2003) 7(2):81–92.10.1080/13284200410001707533
35. Berger AM Gerber LH Mayer DK. Cancer-related fatigue. Cancer (2012) 118(S8):2261–9.10.1002/cncr.2747522488700
36. Reich M Lesur A Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat (2008) 110(1):9–17.10.1007/s10549-007-9706-5
37. Valentine AD Meyers CA. Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer (2001) 92(S6):1694–8.10.1002/1097-0142(20010915)92:6+<1694::AID-CNCR1499>3.0.CO;2-S11598889
38. van’t Spijker A Trijsburg RW Duivenvoorden HJ. Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. Psychosom Med (1997) 59(3):280–93.10.1097/00006842-199705000-000119178339
39. Mehnert A Koch U. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res (2008) 64(4):383–91.10.1016/j.jpsychores.2007.12.00518374737
40. Fulton C. The prevalence and detection of psychiatric morbidity in patients with metastatic breast cancer. Eur J Cancer Care (1998) 7(4):232–9.10.1046/j.1365-2354.1998.00107.x9919110
41. Biringer E Lundervold A Stordal K Mykletun A Egeland J Bottlender R et al. Executive function improvement upon remission of recurrent unipolar depression. Eur Arch Psychiatry Clin Neurosci (2005) 255(6):373–80.10.1007/s00406-005-0577-715793669
42. Wearden A Appleby L. Cognitive performance and complaints of cognitive impairment in chronic fatigue syndrome (CFS). Psychol Med (1997) 27(01):81–90.10.1017/S00332917960040359122311
43. Brezden CB Phillips K-A Abdolell M Bunston T Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2000) 18(14):2695–701.10894868
44. Wieneke MH Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology (1995) 4:61–6.10.1002/pon.2960040108
45. Campos MPO Hassan BJ Riechelmann R Del Giglio A. Cancer-related fatigue: a practical review. Ann Oncol (2011) 22(6):1273–9.10.1093/annonc/mdq45821325448
46. Bower JE. Prevalence and causes of fatigue after cancer treatment: the next generation of research. J Clin Oncol (2005) 23(33):8280–2.10.1200/JCO.2005.08.008
47. Greene D Nail LM Fieler VK Dudgeon D Jones LS. A comparison of patient-reported side effects among three chemotherapy regimens for breast cancer. Cancer Pract (1994) 2(1):57–62.8055007
48. Prue G Rankin J Allen J Gracey J Cramp F. Cancer-related fatigue: a critical appraisal. Eur J Cancer (2006) 42(7):846–63.10.1016/j.ejca.2005.11.02616460928
49. Schwartz AL Nail LM Chen RNS Meek P Barsevick AM King ME et al. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest (2000) 18(1):11–9.10.3109/0735790000902305710701362
50. Minton O Stone P. How common is fatigue in disease-free breast cancer survivors? A systematic review of the literature. Breast Cancer Res Treat (2008) 112(1):5–13.10.1007/s10549-007-9831-118064565
51. Hofman M Ryan JL Figueroa-Moseley CD Jean-Pierre P Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist (2007) 12(Suppl 1):4–10.10.1634/theoncologist.12-S1-417573451
52. Krupp LBMD Elkins LEP. Fatigue and declines in cognitive functioning in multiple sclerosis. Neurology (2000) 55(7):934–9.10.1212/WNL.55.7.93411061247
53. Smith S Sullivan K. Examining the influence of biological and psychological factors on cognitive performance in chronic fatigue syndrome: a randomized, double-blind, placebo-controlled, crossover study. Int J Behav Med (2003) 10(2):162–73.10.1207/S15327558IJBM1002_0512763708
54. Servaes P Gielissen MFM Verhagen S Bleijenberg G. The course of severe fatigue in disease-free breast cancer patients: a longitudinal study. Psychooncology (2007) 16(9):787–95.10.1002/pon.112017086555
55. Meyers CA Albitar M Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer (2005) 104(4):788–93.10.1002/cncr.2123415973668
56. Tchen N Juffs HG Downie FP Yi QL Hu H Chemerynsky I et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 21(22):4175–83.10.1200/JCO.2003.01.11914615445
57. Cruess DG Antoni MH McGregor BA Kilbourn KM Boyers AE Alferi SM et al. Cognitive-behavioral stress management reduces serum cortisol by enhancing benefit finding among women being treated for early stage breast cancer. Psychosom Med (2000) 62(3):304–8.10.1097/00006842-200005000-0000210845343
58. Antoni MH Lehman JM Kilbourn KM Boyers AE Culver JL Alferi SM et al. Cognitive-behavioral stress management intervention decreases the prevalence of depression and enhances benefit finding among women under treatment for early-stage breast cancer. Health Psychol (2001) 20(1):20–32.10.1037/0278-6133.20.6.458a11199062
59. Helgeson VS Reynolds KA Tomich PL. A meta-analytic review of benefit finding and growth. J Consult Clin Psychol (2006) 74(5):797–816.10.1037/0022-006X.74.5.79717032085
60. Berry JM West RL. Cognitive self-efficacy in relation to personal mastery and goal setting across the life span. Int J Behav Dev (1993) 16(2):351–79.10.1177/016502549301600213
61. Rebok GW Balcerak LJ. Memory self-efficacy and performance differences in young and old adults: the effect of mnemonic training. Dev Psychol (1989) 25(5):714.10.1037/0012-1649.25.5.714
62. Cavanaugh JC Green EE. I believe, therefore I can: self-efficacy beliefs in memory aging. In: Lovelace E, editor. Aging and Cognition: Mental Processes, Self-Awareness, and Interventions. Amsterdam: Elsevier (1990). p. 189–230.
63. Bandura A. Self-efficacy: The Exercise of Control. (Vol. ix). New York, NY: W.H. Freeman (1997). 604 p.
64. Cicerone KD Mott T Azulay J Friel JC. Community integration and satisfaction with functioning after intensive cognitive rehabilitation for traumatic brain injury. Arch Phys Med Rehabil (2004) 85(6):943–50.10.1016/j.apmr.2003.07.01915179648
65. Kohler CL Fish L Greene PG. The relationship of perceived self-efficacy to quality of life in chronic obstructive pulmonary disease. Health Psychol (2002) 21(6):610–4.10.1037/0278-6133.21.6.61012433014
66. Aben L Ponds RW Heijenbrok-Kal MH Visser MM Busschbach JJ Ribbers GM. Memory complaints in chronic stroke patients are predicted by memory self-efficacy rather than memory capacity. Cerebrovasc Dis (2011) 31(6):566–72.10.1159/00032462721487221
67. Comijs H Deeg D Dik M Twisk J Jonker C. Memory complaints; the association with psycho-affective and health problems and the role of personality characteristics: a 6-year follow-up study. J Affect Disord (2002) 72(2):157–65.10.1016/S0165-0327(01)00453-012200206
68. Reid LM MacLullich AM. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord (2006) 22(5–6):471–85.10.1159/00009629517047326
69. Valentijn SAM Hill RD Hooren SAHV Bosma H Van Boxtel MPJ Jolles J et al. Memory self-efficacy predicts memory performance: results from a 6-year follow-up study. Psychol Aging (2006) 21(1):165–72.10.1037/0882-7974.21.2.16516594801
70. Paunonen SV Hong RY. Self-efficacy and the prediction of domain-specific cognitive abilities. J Pers (2010) 78(1):339–60.10.1111/j.1467-6494.2009.00618.x20433622
71. McDougall GJ. Rehabilitation of memory and memory self-efficacy in cognitively impaired nursing home residents. Clin Gerontol (2001) 23(3–4):127–39.10.1300/J018v23n03_1119066634
72. Broadbent E Petrie KJ Main J Weinman J. The brief illness perception questionnaire. J Psychosom Res (2006) 60(6):631–7.10.1016/j.jpsychores.2005.10.020
73. Leventhal H Halm E Horowitz C Leventhal EA Ozakinci G. Living with chronic illness: a contextualized, self-regulation approach. In: Sutton SR Baum AS Johnston M, editors. The Sage Handbook of Health Psychology. London: Sage Publications (2004). p. 197–240.
74. Hagger MS Orbell S. A meta-analytic review of the common-sense model of illness representations. Psychol Health (2003) 18(2):141–84.10.1080/088704403100081321
75. Schuurs A Green HJ. A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psychooncology (2013) 22(5):1043–9.10.1002/pon.310222570263
76. Petrie KJ Jago LA Devcich DA. The role of illness perceptions in patients with medical conditions. Curr Opin Psychiatry (2007) 20(2):163–7.10.1097/YCO.0b013e328014a87117278916
77. Fardell JE Vardy J Johnston IN Winocur G. Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther (2011) 90(3):366–76.10.1038/clpt.2011.11221814191
78. Mar Fan H Clemons M Xu W Chemerynsky I Breunis H Braganza S et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer (2008) 16(6):577–83.10.1007/s00520-007-0341-917972110
79. Gehring K Roukema JA Sitskoorn MM. A review of recent studies on interventions for cognitive deficits in patients with cancer. Expert Rev Anticancer Ther (2012) 12(2):255–69.10.1586/era.11.20222316373
80. Wilson BA. Towards a comprehensive model of cognitive rehabilitation. Neuropsychol Rehabil (2002) 12(2):97–110.10.1080/09602010244000020
81. McDougall GJ Jr. Memory improvement program for elderly cancer survivors. Geriatr Nurs (2001) 22(4):185–90.10.1067/mgn.2001.117916
82. Ferguson RJ Ahles TA Saykin AJ McDonald BC Furstenberg CT Cole BF et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology (2007) 16(8):772–7.10.1002/pon.1133
83. Poppelreuter M Weis J Bartsch HH. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol (2009) 27(2):274–96.10.1080/0734733090277604419337933
84. McDougall GJ Becker H Acee TW Vaughan PW Delville CL. Symptom management of affective and cognitive disturbance with a group of cancer survivors. Arch Psychiatr Nurs (2011) 25(1):24–35.10.1016/j.apnu.2010.05.00421251599
85. Von Ah D Carpenter J Saykin A Monahan P Wu J Yu M et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat (2012) 135(3):799–809.10.1007/s10549-012-2210-622918524
86. Ferguson RJ McDonald BC Rocque MA Furstenberg CT Horrigan S Ahles TA et al. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology (2012) 21(2):176–86.10.1002/pon.187822271538
87. Cherrier MM Anderson K David D Higano CS Gray H Church A et al. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci (2013) 93(17):617–22.10.1016/j.lfs.2013.08.01124012579
88. Ercoli LM Castellon SA Hunter AM Kwan L Kahn-Mills BA Cernin PA et al. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav (2013) 7(4):543–53.10.1007/s11682-013-9237-023955490
89. Kesler S Hadi Hosseini SM Heckler C Janelsins M Palesh O Mustian K et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clin Breast Cancer (2013) 13(4):299–306.10.1016/j.clbc.2013.02.00423647804
90. Randolph C Tierney MC Mohr E Chase TN. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol (1998) 20(3):310–9.10.1076/jcen.20.3.310.8239845158
91. Duff K Beglinger LJ Schoenberg MR Patton DE Mold J Scott JG et al. Test-retest stability and practice effects of the rbans in a community dwelling elderly sample. J Clin Exp Neuropsychol (2005) 27(5):565–75.10.1080/1380339049091836316019633
92. McKay C Casey JE Wertheimer J Fichtenberg NL. Reliability and validity of the RBANS in a traumatic brain injured sample. Arch Clin Neuropsychol (2007) 22(1):91–8.10.1016/j.acn.2006.11.00317141467
93. Dikmen SS Heaton RK Grant I Temkin NR. Test-retest reliability and practice effects of expanded Halstead-Reitan neuropsychological test battery. J Int Neuropsychol Soc (1999) 5(4):346–56.10.1017/S135561779954405610349297
94. Carlson MC Xue Q-L Zhou J Fried LP. Executive decline and dysfunction precedes declines in memory: the women’s health and aging study II. J Gerontol A Biol Sci Med Sci (2009) 64A(1):110–7.10.1093/gerona/gln00819182230
95. Wagner LI Lai JS Cella D Sweet JSF. Chemotherapy-related cognitive deficits: development of the FACT-Cog instrument. Ann Behav Med (2004) 27:S10.
96. Jacobs SR Jacobsen PB Booth-Jones M Wagner LI Anasetti C. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manage (2007) 33(1):13–23.10.1016/j.jpainsymman.2006.06.01117196903
97. Man DWK Fleming J Hohaus L Shum D. Development of the brief assessment of prospective memory (BAPM) for use with traumatic brain injury populations. Neuropsychol Rehabil (2011) 21(6):884–98.10.1080/09602011.2011.62727022150453
98. Aaronson NK Ahmedzai S Bergman B Bullinger M Cull A Duez NJ et al. The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 85(5):365–76.10.1093/jnci/85.5.3658433390
99. Jocham HR Dassen T Widdershoven G Halfens RJG. Quality-of-life assessment in a palliative care setting in Germany: an outcome evaluation. Int J Palliat Nurs (2009) 15(7):338–45.10.12968/ijpn.2009.15.7.4342419648849
100. Bjordal K de Graeff A Fayers PM Hammerlid E van Pottelsberghe C Curran D et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. Eur J Cancer (2000) 36(14):1796–807.10.1016/S0959-8049(00)00186-610974628
101. Kessler RC Andrews G Colpe LJ Hiripi E Mroczek DK Normand S-LT et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med (2002) 32(6):959–76.10.1017/S003329170200607412214795
102. Carver CS Antoni MH. Finding benefit in breast cancer during the year after diagnosis predicts better adjustment 5 to 8 years after diagnosis. Health Psychol (2004) 23(6):595–8.10.1037/0278-6133.23.6.59515546227
103. Helgeson VS Snyder P Seltman H. Psychological and physical adjustment to breast cancer over 4 years: identifying distinct trajectories of change. Health Psychol (2004) 23(1):3–15.10.1037/0278-6133.23.1.314756598
104. Huckans M Pavawalla S Demadura T Kolessar M Seelye A Roost N et al. A pilot study examining effects of group-based cognitive strategy training treatment on self-reported cognitive problems, psychiatric symptoms, functioning, and compensatory strategy use in OIF/OEF combat veterans with persistent mild cognitive disorder and history of traumatic brain injury. J Rehabil Res Dev (2010) 47(1):43–60.10.1682/JRRD.2009.02.001920437326
105. Schuurs A Green HJ. Clinician’s Manual for “Responding to Cognitive Concerns” (ReCog): A Four-Session Cognitive Rehabilitation Program for Adults Recovering from Cancer. Gold Coast, QLD: Griffith University (2009).
106. Schuurs A Green HJ. Participant’s Manual for “Responding to Cognitive Concerns” (ReCog): A Four-Session Cognitive Rehabilitation Program for Adults Recovering from Cancer. Gold Coast, QLD: Griffith University (2009).
107. Fayers P Aaronson N Bjordal K Groenvold M Curran D Bottomley A et al. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer (2001).
108. Morris SB. Estimating effect sizes from pretest-posttest-control group designs. Organ Res Methods (2008) 11(2):364–86.10.1037/a001469919271847
109. Heritier SR Gebski VJ Keech AC. Inclusion of patients in clinical trial analysis: the intention-to-treat principle. Med J Aust (2003) 179(8):438–40.14558871
110. Chelune GJ Naugle RI Luders H Sedlak J Awad IA. Individual change after epilepsy surgery: practice effects and base-rate information. Neuropsychology (1993) 7(1):41–52.10.1037/0894-4105.7.1.41
111. Baron RM Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol (1986) 51(6):1173–82.10.1037/0022-3514.51.6.11733806354
112. Howell DC. Statistical Methods for Psychology. Belmont, CA: Thomson Higher Education (2007).
113. Vardy J Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol (2007) 63(3):183–202.10.1016/j.critrevonc.2007.06.00117678745
114. Leon AC Davis LL Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res (2011) 45(5):626–9.10.1016/j.jpsychires.2010.10.00821035130
115. Schagen SB Das E van Dam FSAM. The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients. Psychooncology (2009) 18(6):674–8.10.1002/pon.145419021129
116. Silverberg ND Wertheimer JC Fichtenberg NL. An effort index for the repeatable battery for the assessment of neuropsychological status (RBANS). Clin Neuropsychol (2007) 21(5):841–54.10.1080/13854040600850958